entertainment -WSS

entertainment

author：entertainment 2025-09-30 22:03:50 - browse：857

Treeline Northwest — AP Photo/Ted S. Warren

Josh Bilenker’s last company, Loxo Oncology, was purchased by Eli Lilly for $8 billion. No surprise, then, that his next effort has already raised at least $473 million in funding from private investors even before telling the public what, exactly, it is working on.

Treeline Biosciences, the new venture by Bilenker and Jeffrey Engelman, formerly Novartis’s top cancer researcher, has hired more than 130 people across three research sites in little more than a year, according to a company blog post, regulatory filings, and STAT reporting.

Treeline’s website doesn’t mention a single drug target or disease. In a paper published last year in Nature Cancer, Engelman and several colleagues reviewed the history of a class of cancer drugs called PI3 kinase inhibitors.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： After affirmative action ruling, medical educators look to 'holistic review'
Next article： Boston competes with Raleigh

Wikipedia

WSS

With FDA staff opposed to Sarepta therapy, top official intervened

Study: Lilly Alzheimer's therapy slowed patients' cognitive decline

Death of patient in Alzheimer’s trial raises question of possible risks

Pancreatic cancer early detection could be helped by AI

3 hurdles to bringing medical devices to the U.S. market

Boston competes with Raleigh

focus

entertainment

hotspot

In age of alternative facts, a scholarly course on calling out crap

Why you shouldn’t ask, “What country has the best health care?”

Tori Bowie and the unacceptable rates of Black maternal death

Medicare drug price negotiation legal challenge met with skepticism

In Memoriam: Notable people who died in 2023

CDC concerned about possible undetected monkeypox spread in U.K.

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

With FDA staff opposed to Sarepta therapy, top official intervened

Drug repurposing or repositioning? The language matters

Biogen walks away from Aduhelm, years after polarizing approval

entertainment

Death of patient in Alzheimer’s trial raises question of possible risks

How generative AI ratchets up security threats for health systems

Why Medicare shouldn’t cover every FDA

Wegovy leads to weight loss. Can it treat depression, too?

Venture capital firm's plans to take over Akron hospital face hurdles

Why Medicare shouldn’t cover every FDA

focus

Wikipedia

focus

knowledge